China
Africa
Explore chapters and articles related to this topic
Genital Herpes/Herpes Genitalis
Published in Charles Theisler, Adjuvant Medical Care, 2023
Genital herpes is one of the most common sexually transmitted diseases in the U.S. Herpes genitalis can be caused by herpes simplex virus (HSV-1), but is mostly caused by HSV-2, and is characterized by a high rate of recurrences. Most people with the virus don’t have symptoms. When symptoms do occur, they typically include small blisters in the genital region that break open to form painful ulcers. Even without signs of the disease, herpes can still be spread to sex partners.1
DRCOG MCQs for Circuit A Questions
Published in Una F. Coales, DRCOG: Practice MCQs and OSCEs: How to Pass First Time three Complete MCQ Practice Exams (180 MCQs) Three Complete OSCE Practice Papers (60 Questions) Detailed Answers and Tips, 2020
Deep dyspareunia can occur with: Pelvic inflammatory disease (PID). Β. Vaginismus.Bartholin's cyst.Herpes genitalis infection.Endometriosis.
Aquatic Plants Native to Europe
Published in Namrita Lall, Aquatic Plants, 2020
Isa A. Lambrechts, Lydia Gibango, Antonios Chrysargyris, Nikolaos Tzortzakis, Namrita Lall
Mixtures of T. natans with other plants (Wisteria floribunda, Terminalia chebulae, Coix lachryma-jobi, Ganoderma lucidum, and Elfuinga applanata) can be used as an effective and fast relieving agent for the symptoms of Herpes genitalis. The mixture was able to reduce the duration of the symptoms to up to half (from 10.9 days to 4.9 days) (Hijikata et al. 2007).
The efficacy of oral acyclovir during early course of pityriasis rosea: a systematic review and meta-analysis
Published in Journal of Dermatological Treatment, 2019
Hua-Ching Chang, Chih-Wei Sung, Ming-Hsiu Lin
In contrast to the studies included in the current meta-analysis, two publications reported less encouraging results concerning the efficacy of oral acyclovir for treating PR. One triple-blind trial recruited 27 patients with PR and randomly assigned them to two treatment groups: oral acyclovir (800 mg 5 times daily for 1 week) or placebo. That study examined only the number of days required to resolve PR, and they observed no significant difference between the two groups with respect to the duration required for disease resolution (21). However, limited clinical information was provided by that study concerning the rate of incremental improvement during weekly follow-ups. Another case report described one patient who developed PR after 5 months of continuous acyclovir treatment for herpes genitalis (22). However, this case used a lower dose and frequency of acyclovir (400 mg twice daily) compared with other trials focusing on the efficacy of acyclovir for treating PR.
The use of antiviral drugs in children
Published in Journal of Chemotherapy, 2022
Marco Antonio Motisi, Agnese Tamborino, Sara Parigi, Luisa Galli, Maurizio de Martino, Elena Chiappini
Herpes viruses (HSV) are capsular viruses containing double helix DNA and are members of the Herpesviridae family. There are two distinct types of HSV: HSV-1 (Herpes labialis) involves the skin of the face, chest, and abdomen; HSV-2 (Herpes genitalis) involves the genitals and perineal skin. Both viruses can cause disease in newborns [21]. The incidence of neonatal infection in the United States is estimated to be 1 per 2000–3000 live births and is higher in the United States than in Europe. HSV is frequently transmitted to newborns at birth, either through the infected maternal genital tract, or by ascending infection, sometimes with apparently intact membranes. The risk of HSV infection in a healthy infant born vaginally to a mother with primary genital infection is estimated at 25–60%, while that of an infant born to a mother who eliminates HSV due to reactivation of the infection is 2%. Neonatal HSV infection may occur as a systemic infection involving mainly the liver, lungs and, in 60–75% of cases, the central nervous system (CNS); alternatively, it may occur as a localized infection involving skin, eyes and mouth (skin-eye-mouth disease, SEM) or as a localized CNS disease. Neonatal herpes infections are often severe, with high mortality and morbidity even when treated with antiviral therapy. Acyclovir should be administered to all newborns with neonatal HSV, regardless of the clinical picture [22]. The dose of acyclovir proven to be effective is 60 mg/kg/day in three intravenous administrations, for 14 days if the infection is localized to the skin, eyes and mouth, and for 21 days in the case of systemic infection or encephalitis [23].
Herpetic Anterior Uveitis – Analysis of Presumed and PCR Proven Cases
Published in Ocular Immunology and Inflammation, 2019
Ron Neumann, Dana Barequet, Amir Rosenblatt, Radgonde Amer, Yael Ben-Arie-Weintrob, Tamar Hareuveni-Blum, Vicktoria Vishnevskia-Dai, Eyal Raskin, Oren Blumenfeld, Shiri Shulman, Juan M. Sanchez, Victor Flores, Zohar Habot-Wilner
The cohort comprised 54 (48.2%) HSV eyes, 34 (30.4%) VZV eyes, 2 (1.8%) CMV eyes, and 22 (19.6%) unspecified HAU eyes. Seventeen/112 (15.2%) eyes underwent PCR analysis for detection of herpes virus DNA. Thirteen/54 (24%) eyes diagnosed with HSV were confirmed by PCR (12 eyes HSV-1 and 1 eye HSV-2), while the other eyes had corneal findings including a corneal dendrite. The HSV-2 PCR proven case was the only case with a history of herpes genitalis. Most of the eyes diagnosed with VZV (32/34 (94.1%)) had active or past episodes of herpes zoster ophthalmicus, and the diagnosis of the remaining 2/34 (5.9%) eyes, which presented with zoster sine herpete, was confirmed by PCR. The classification of all the eyes (2/2 (100%)) diagnosed with CMV was confirmed by PCR. The association between disease type according to herpes pathogen and patients’ characteristics and clinical findings is summarized in Table 4. There was no difference in the distribution of age and gender between patients with HSV or VZV. The two patients with CMV, were both males and presented at a younger age than the HSV and VZV patients. Eyes with HSV compared to VZV had significantly more recurrent disease, corneal involvement, KPs, iris atrophy, elevated IOP, and posterior synechia (p < 0.05). Patients with VZV had significantly more IMN treatments and were significantly more likely to have a history of systemic herpetic disease (p < 0.05). Nevertheless, none of the aforementioned clinical findings were pathognomonic to any herpes type, and all were seen in eyes with HSV or VZV. In contrast, the CMV patients did not have corneal manifestations or posterior synechia.